2Tejani A, Emmett L. Minimal change disease [ M ]//Massry SG, Glassock RJ, ed. Textbook of Nephrology. 4th ed. Philadelphia:Lippincott Williams & Wilkins ,2001:694 -699.
3Schnaper HW, Robson AM, Kopp JB. Nephrotic syndrome : minimal change nephropathy, focal segmental glomerulosclerosis, and collapsing glomerulopathy [ M ]//Schrier RW, ed. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott Williams & Wilkins ,2007 : 1585 - 1672.
5Olson JL. The nephrotic syndrome : minimal change disease. Schwartz MM. Focal segmental glomerulosclerosis [ M ]//Jennette JC, Olson JL, Schwartz MM, et al,ed. Heptinstall's Pathology of the Kidney. 6th ed. Philadephia : Lippincott William & Wilkins, 2007 : 125 - 204.
6D'Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal [J]. Am J Kid Dis,2004,43:368 - 382.
7Chun MJ, Korbet SM,Schwartz MM,et al. Focal segmental glomerulosclerosis in nephritic adults: presentation, prognosis and response to therapy of the histologic variants [J]. J Am Soc Nephrol, 2004,15:2169 -2177.
8Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids [J]. Clin Pharmacokinet,2005 ,44 :61 - 98.
9Buttgereit F, Saag KG, Cutolo M, et al. The molecular basis for the effectiveness, toxicity and resistance to glucocorticoids : focus on the treatment of rheumatoid arthritis [J]. Scand J Rheumatol, 2005, 34:14 -21.
10Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis[ J]. Semin Nephrol,2003 ,23 : 141 - 146.
